Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

ClinicalTrials.gov ID: NCT04660760

Public ClinicalTrials.gov record NCT04660760. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study

Study identification

NCT ID: NCT04660760
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Academic and Community Cancer Research United; Other
Enrollment: 116 participants

Conditions and interventions

Conditions

Interventions

Paclitaxel Drug
Quality-of-Life Assessment Other
Ramucirumab Biological
Trifluridine and Tipiracil Hydrochloride Drug

Drug · Other · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 15, 2021
Primary completion: Jul 30, 2024
Completion: May 30, 2026
Last update posted: Mar 31, 2024

2021 – 2026

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham Cancer Center	Birmingham	Alabama	35233	Not yet recruiting
Mayo Clinic in Arizona	Scottsdale	Arizona	85259	Recruiting
Arizona Clinical Research Center	Tucson	Arizona	85715	Withdrawn
USC / Norris Comprehensive Cancer Center	Los Angeles	California	90033	Recruiting
Mayo Clinic in Florida	Jacksonville	Florida	32224-9980	Recruiting
Cleveland Clinic-Weston	Weston	Florida	33331	Recruiting
Emory University Hospital/Winship Cancer Institute	Atlanta	Georgia	30322	Withdrawn
Carle Cancer Center NCI Community Oncology Research Program	Urbana	Illinois	61801	Withdrawn
University of Iowa/Holden Comprehensive Cancer Center	Iowa City	Iowa	52242	Not yet recruiting
Cancer Center of Kansas - Wichita	Wichita	Kansas	67214	Withdrawn
Metro Minnesota Community Oncology Research Consortium	Saint Louis Park	Minnesota	55416	Completed
University of Nebraska Medical Center	Omaha	Nebraska	68198	Withdrawn
Vanderbilt University/Ingram Cancer Center	Nashville	Tennessee	37232	Recruiting
Saint Vincent Hospital Cancer Center Green Bay	Green Bay	Wisconsin	54301	Recruiting
Aurora Cancer Care-Milwaukee West	Wauwatosa	Wisconsin	53226	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04660760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 31, 2024 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04660760 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →